►
From YouTube: Open Source Antibiotics Science Update Jan 29 2021
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/53
On the call: Professor Matthew Todd, Dr Dana Klug, Giada Sabatino (UCL), Dr Chris Swain (Cambridge MedChem Consulting), Anthony Sama (citizen contributor)
A
Which
is
here
and
just
quickly
to
work
through
some
things.
So
all
the
chemistry
is
stalled
at
the
moment
just
while
people
are
out
of
the
lab
and
I've
got
lockdown
restrictions
and
stuff,
but
that
will
start
to
lift
in
the
coming
weeks,
but
we
do
have
some
planning
to
do
and
we
obviously
have
stuff
left
over
from
last
time.
So
the
quickest
thing,
I
think,
would
be
whether
we've
had
update
on
the
cider
talks
stuff
there.
You
know
anything
on
that,
okay,
so
nothing
on
that.
A
I
think
I
might
pursue
that
this
week
and
just
say:
what's
the
plan,
because
it's
sometimes
quite
difficult
for
people,
because
they
have
to
pause
things
in
the
lab
and
in
some
cases
I
think
in
this
case
a
junior
student
was
involved
and
we
have
this
policy
now
eco,
where
junior
students
aren't
supposed
to
be
in
lab
during
lockdown,
so
I'll
chase
that
so
that's
on
me.
A
Notes
for
myself
and
then
the
I
mean
the
next
thing
was
on
the
basis
of
the
synthetic
targets
that
were
really
clearly
shown.
Last
time,
dana's
been
doing
the
the
sort
of
shopping
list.
So
are
you
happy
to
talk
us
through
this
a
little
bit.
B
Yeah,
I
think
this
sort
of
schematic
covers
most
of
the
proposed
compounds
that
were
in
the
list
from
last
week,
some
of
them
that
we'd
have
to
sort
of
do
chemistry
from
scratch.
I
said
I
decided
were
kind
of
lower
priority,
but
anyway,
so
the
first
is
these
compounds
that
can
be
made
through
the
suzuki
reaction
that
we've
been
doing
so
we
talked
about
doing
this
fluorinated
pyridine,
so
that
compound
is
we
can
buy
the
aniline
we
have
at
ucl.
B
So
this
is
just
according
to
the
inventory,
so
hopefully
it's
actually
there,
but
it
should
be,
and
then
we
talked
about
putting
some
more
polar
functionality
out
here.
So
I
thought
that
maybe
we
could
start
with
this
chlorobromobenzene
and
then
just
do
snar,
followed
by
the
miura
reaction
we
could
sort
of
just
plug
in
some
amines.
So
these
were
some
suggestions
from
last
time
as
well
as
I
thought.
Maybe
these
piperidines
or
pipperzine
sorry
would
might
be
interesting
for
putting
in
some
polarity
out
there.
B
B
B
So
there's
that
then
the
one
pot
method-
let's
see
so
we
had
talked
about
putting
the
fluoro
out
here-
that
isocyanide
is
commercially
available.
I
think
it's
probably
the
most
expensive
thing
on
the
list.
B
Where
is
it?
It's
62
pounds
per
gram,
but
I
think
it
is
worth
buying
because
you
can
make
the
isocyanide
and
lori's
given
us
the
procedure
for
that.
B
But
I
was
thinking
that
the
first
time
we
do
it,
it
would
be
good
to
have
to
sort
of
not
have
to
mess
around
with
this,
and
then
we
can
just
sort
of
get
a
feel
for
how
the
one
plot
procedure
works
and
then
obviously
these
two
building
blocks
will
use
a
lot
of
so
the
chu
amino
pyridine.
We
have
the
aldehyde
we
can
buy
and
this
ytterbium
catalyst
we
we
can
buy.
It's
actually
not
that
expensive.
C
B
So
lori
and
some
chemists
at
northeastern
have
done
this
procedure
before
so
we
have
their
experimental
that
we
can
follow,
and
then
these
are
some
of
the
aldehydes
that
we
were
sort
of
thinking
about
with
the
five-membered
heterocycles.
B
So
the
oxazole
is
pretty
expensive,
but
the
other
ones
are
available.
So
we
can
go
ahead
and
purchase
those,
and
then
we
just
need
sort
of
one
reagent
for
making
the
isocyanides
that
we
don't
have.
So
I
can
go
ahead
and
buy
that
and
then
we
can
see
what
sort
of
arrow
amines
we
have
that
we
would
might
want
to
explore
great.
B
And
then
the
core
that
chris
you
suggested,
I
did
a
quick
scifinder
search
and
I
think
our
best
bet
is
to
go
with
this
almond
coupling
with
aerobromides.
So
we
have
a
bunch
of
those
at
ucl.
These
are
some
of
the
ones
I
picked
out
that
I
thought
might
be
interesting
and
then
everything
else
for
that
chemistry
we
have
we,
oh,
we
have
to
buy
the
starting
material,
but
otherwise
we're
good
to
go.
B
E
A
Yeah,
that
was
the
that
was
your
advantage.
The
advantage
here,
yeah.
B
A
B
A
Great
thanks,
perfect.
The
other
thing
that
we,
I
guess
needed
to
talk
about
was
the
the
mechanism
of
action
stuff
from
last
time.
So
we
had
the
the
session
with
lee
last
time,
which
was
great,
and
we
worked
through
a
few
things
there
and
dana's
been
through
the
last
meeting
and
made
notes
here
which
looked
really
comprehensive,
which
is
great.
There
were,
you
know
some
suggested
hot
targets.
A
I
guess
that
we
should
maybe
zoom
in
on,
and
there
were
some
there
was
some
suggestion
of
follow-up
experiments
that
could
be
known
did
so
did
we
send
you
an
email,
dana
about
follow-up.
B
Mm-Hmm
yeah,
I
think
I
think
you
probably
have
it
too,
but
in
any
case
he
suggested
that
the
first
thing
we
do
was
to
repeat
this
experiment
because
he
said
karim
who's.
His
tech
felt
we
could
have
captured
more
proteins
if
he'd
started
with
more
lysates,
so
lee
said,
I
suggest
we
repeat
the
experiment.
B
For
that
reason,
so
I
don't
know
I
mean
if
that's
something
that
we
need
to
worry
about,
funding
for
or
if
we
can
just
go
ahead
and
do
it,
but
it
seems
like
that
that
seems
like
a
reasonable
first
step
and
then
it
sort
of
gives
us
time
in
the
meantime,
to
sort
of
do
some
more
digging
on
these
targets
that
were
pulled
out.
A
B
I
don't
think
they
said
anything
about
that
all
right.
So
that's
something
we
need
to
ask
them.
A
Yeah,
because
I
I
suspect
that'll
be
enough
for
that,
but
I
I
don't
want
to
commit
in
public
to
them
doing
an
experiment,
but
I
think
that
yeah
so
I'll
ask
a
question
about
about
money
there
for
sure-
and
I
guess
that's
also
irrelevant
to
the
idea
of
any
follow-up
experiments,
because
there
are
some
things
there
to
do
with
a
more.
You
know,
a
more
unbiased
approach
about
trying
to
find
out
how
the
protium
is
disturbed.
If
you
give
the
compound-
but
I
think
quite
expensive,
so
I'll
try
and
engage
really
off
this
meeting.
A
B
A
But,
as
you
say
in
the
meantime,
yes,
there
are
things
we
can
do
and-
and
I
was
just
putting
some
so
yeah-
we
had
this-
the
giada
put
together
last
time,
which
has
all
the
links
for
the
various
proteins
that
were
up
there
and
then
based
on
the
I
think,
based
on
the
results
to
date
from
memory
it
was,
it
was
the
two
these
two
mqa1
is
that
one
of
the
ones
that's
there
yeah
mql1
is
one
of
the
top
and
poor
and
pure
d
was
one
of
the
other
ones.
A
If
I
remember
correctly-
and
so
you
know
the
question-
I
guess
when
you
when
you
see
things
like
that,
is
whether
these
are
known
targets
already,
you
know,
is
somebody
already
designing
something
versus
these?
Does
somebody
already
have
the
protein?
Is
someone
already
investigating
as
a
target?
Does
somebody
already
have
it
in
an
assay,
and
is
it
known
somehow
to
be
an
essential
target?
A
I
don't
know
if
you
wanted
to
to
take
on
some
of
this,
maybe
as
a
bit
of
lift
following
up
with
what
you
do,
because
this
is
kind
of
relevant
to
your
your
project,
which
you're
officially
starting
in
a
couple
of
weeks
right
but
okay
yeah,
which
is
you
know
at
the
moment,
is
online
jada
was
was
meant
to
be
doing
a
practical
project,
and
that
may
happen
later
in
the
year.
If
we
can,
if
we
can
lessen
restrictions,
but
at
the
moment
we're
in
a
virtual
mode.
A
So
this
seems
like
quite
a
good
thing
to
get
involved
in
sort
of
seeing
whether
or
not
any
of
these
targets
are.
You
know
obvious
things
we
should
be
looking
at
already
so
yeah
are
they?
Are
they
known
targets?
Is
anyone
working
on
them
recently
in
a
way
that
we
might
be
able
to
collaborate
with
them
to
see
if
there's
any
inhibition
or
you
know,
and
so
on
and
so
on
and
so
on?
I
guess
maybe.
E
A
A
Find
and
then
based
on
what
you
find
we
can
sort
of
help
and
advise
about
whether
we've
answered
all
the
kind
of
obvious
questions.
B
A
However,
you
know
if
there
is
you
know
if
you
know,
let's
say
in
ucl
right,
there's
someone
who
is
already
looking
at
one
of
these
targets
and
happens
to
have
an
assay
up
and
running
that
we
could.
We
can
evaluate,
it
would
be
a
bit
of
a
bit
embarrassing
if
we
missed
that.
So,
once
you've
had
a
look
at
the
couple
which
are
the
most
promising
yeah
just
see,
if
you
can
find
out
something
about
whether
any
of
these
others
are.
You
know
existing
known
drug
targets
to
the
antimicrobial
community.
F
A
G
B
It,
and
so
these
are
all
the
targets
that
I
listed
above,
but
then
you
know
I
just
screenshotted
the
excel
sheet
with
the
actual
full
change
values.
I
thought
that
might
be
useful
for
us
to
look
at.
B
A
Yeah,
yeah,
okay
and
and
so
they're
all
much
of
a
mattress
in
terms
of
values.
I
guess
soda
is
the
best,
but
that
soda
doesn't
have
an
up
or
down
right
now.
B
A
A
A
Okay,
great,
that
gives
us
a
starting
point
and
I'll
follow
up
with
lee
after
this
meeting
I'll
send
all
them.
A
Okay,
I
think
that
was
that
was
all
I
I
was
going
to
say
there
again.
There
are
these
little
actions
that
people
can
look
at
if
they
get
some
time,
I'm
right
in
the
middle
of
writing
the
second
newsletter,
just
because
it's
on
the
second
one
is
on
the
mo
ligos
project,
where
we're
meeting
in
a
week
or
so
so
I'll
send
out
something
about
that.
The
the
mycelma
project
successfully
copied
your
signup
sheet
dana.
Thank
you
great.
A
All
right
was
there
anything
else.
Anyone
wanted
to
ask
before
we
before
we
wrap
oh
yeah,
there
was
a
question
anthony
you
asked
about
getting
lori's
compounds
evaluated.
Look.
I
think
that
there
could
be
some
some
traction
in
that
from
paul
stapleton,
because
we
are
otherwise
going
to
be
waiting
for
quite
a
while
before
we
next
batch
of
compounds.
So
I'll
ask
him
if
he's
willing
to
screen
those
on
their
own,
because
it's
only
like
five
or
six
compounds,
I
think
so.
A
You
know
sometimes
there's
a
lot
of
effort
to
start
an
asset
up
and
do
that
number
of
compounds.
But
I'll
ask
him
to
see.
If
he's
see,
if
he's
interested,
so
we
could
at
least
get
that
done
while
we're,
while
we're.
A
A
Yeah
right
right
so
it'd
be
definitely
useful
to
have
I'll
ask
him
if
it's
if
it's
gonna
be
okay,.